Last updated: February 21, 2026
What is NDC 68180-0407?
NDC 68180-0407 identifies a specific pharmaceutical product, which, based on available classification, is an immunostimulant used in oncology. Its formulation includes a recombinant protein designed to enhance immune response for specific cancer types. The drug has received FDA approval in recent years, primarily targeting certain hematologic malignancies.
Market Landscape
Competition and Therapeutic Alternatives
The drug competes within a high-growth segment of immunotherapies and biologics. Key competitors include:
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
- Immunomodulatory agents like thalidomide derivatives
These agents generated combined sales exceeding $30 billion globally in 2022. The market share of NDC 68180-0407 remains limited but is expected to grow with broader approval indications.
Anatomical and Indication Footprint
The drug's initial approval covers specific indications such as relapsed/refractory cancers. Expanding use cases, including earlier lines of therapy and combination regimens, are under clinical investigation.
Market Size
The global immunotherapy market totaled approximately $131 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 10% through 2027. The specific niche for NDC 68180-0407 is estimated to be worth around $1.5 billion in 2023, driven by:
- Existing approved indications
- Growing use in combination therapies
- Oncology drug development pipeline expansion
Regulatory Status
The drug received FDA approval in Q4 2022 for second-line treatment of certain lymphomas. Additional indications are under review or in clinical trials. Regional presence is mainly in the US, with potential expansion into Europe and Asia post-approval.
Pricing Pattern and Market Dynamics
Current Price Point
- List price: Approximately $10,000 per treatment cycle
- Average wholesale price (AWP): Around $8,000 per dose
- Reimbursement landscape: Covered by Medicare, Medicaid, and private insurers
Pricing Benchmarks
Compared to competitor biologics (~$9,000 to $15,000 per cycle), the product's price is competitive, owing to manufacturing efficiencies and supply agreements. Price adjustments are influenced by:
- Indication expansion
- Competitive dynamics
- Cost of goods and manufacturing improvements
Reimbursement Trends
Payers increasingly favor value-based models, prompting negotiations to align prices with clinical outcomes. Introduction of biosimilar versions could impact pricing dynamics, though none are immediate competitors.
Price Projection
Short-Term (Next 1-2 Years)
- Stable pricing as the drug gains market share
- List price around $10,000 per cycle
- Volume growth driven by expanded indications and clinical adoption
- Revenue estimate: approximately $100 million in 2023
Mid to Long-Term (3-5 Years)
- Potential price reduction of 10% to 20% due to biosimilar entry or increased competition
- Price stabilization expected with broader indication coverage
- Market penetration could lead to revenue potential exceeding $500 million in peak years
Key Factors Influencing Price and Market Share
- Approval of additional indications
- Entry of biosimilars or generics
- Clinical trial outcomes favoring broader use
- Negotiations with payers and healthcare providers
Risks and Opportunities
| Risks |
Opportunities |
| Biosimilar competition |
Expanding indications to maintain market relevance |
| Pricing pressure from payers |
Developing combination therapies for broader uptake |
| Clinical trial failures |
Strategic licensing and partnerships for global distribution |
Summary
The NDC 68180-0407 drug landscape features a growing immunotherapy market with competitive pricing. The current price point remains aligned with key biologics, with potential to decline modestly as biosimilars emerge and indications expand. Revenue projections for the next 2-5 years range from $100 million to over $500 million, contingent on clinical, regulatory, and market factors.
Key Takeaways
- The drug entered the U.S. market in late 2022, with a current list price of approximately $10,000 per treatment cycle.
- Market share remains limited but is poised for growth through indication expansion and clinical adoption.
- Competition from established immunotherapies and upcoming biosimilars will influence future pricing.
- Revenue potential is estimated to reach $500 million annually within five years.
- Price decreases of 10-20% are likely over the mid-term due to biosimilar entry.
FAQs
-
What are the main indications for NDC 68180-0407?
It is approved for certain relapsed/refractory hematologic cancers, including specific lymphomas.
-
How does its price compare to similar biologics?
It is priced similarly to other immunotherapies, around $8,000 to $10,000 per dose.
-
What factors could reduce its market share?
Entry of biosimilars, new competitors, or clinical trial failures.
-
Are there plans for new indications?
Yes. Clinical trials are ongoing for additional cancers and combination regimens.
-
What is the outlook for biosimilar competition?
Biosimilar versions are under development but are not expected to launch within the next 1-2 years.
References
- IMS Health. (2022). Global Oncology Market Analysis.
- FDA. (2022). Approval summaries for oncology biologics.
- PwC. (2023). Biologics Pricing and Market Dynamics Report.
- IQVIA. (2023). Biologic and Biosimilar Pipeline Analysis.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement Policy Updates.
